Cliantha Research chooses Acceliant's eClinical Suite for clinical trial data management needs

Acceliant, a global technology provider of innovative clinical trial data management solutions, today announced that Cliantha Research, a leading global Contract Research Organization, has chosen Acceliant's eClinical Suite for their clinical trial data management needs. Acceliant's integrated e-PRO/EDC system offers a superior solution by allowing all the study data to be readily available, eliminating the integration costs.

Speaking of the partnership, Hitesh Chauhan , Associate Director of Biometrics at Cliantha Research, said, "We evaluated and selected Acceliant eClinical Suite because we found it to be very user-friendly and superior to several other products. Besides being a platform with best-in-class features, Acceliant's eClinical Suite is architected process and system wise to drive efficiency, lower costs and accelerate clinical trial studies."

On the occasion, Ven Thangaraj, CTO of Acceliant, said, "The Life Sciences industry is going through dramatic changes and pressures to innovate while keeping costs under control. Acceliant is one of the few integrated EDC-ePRO platforms with innovative workflows and built-in mobility which allows data management from anywhere, anytime."

Santhosh S. Nagaraj, Acceliant's India Sales Head , commented, "We are proud to be associated with Cliantha Research and helping them in their clinical studies. Our differentiation as a robust platform that accelerates trials through efficient data management is what helped us win. We look forward to a successful long-term relationship and continued growth in India."

Acceliant is also pleased to announce its participation at the BioPharma Asia Convention 2013, one of the largest annual biopharmaceutical industry gatherings in Asia. The convention will be held in Singapore from March 18-21. Acceliant will be in Booth #D24 and will showcase its comprehensive eClinical Suite, interact with global experts, and explore more partnership opportunities.